

RESEARCH ARTICLE SUMMARY

CORONAVIRUS

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Qian Zhang *et al.*

INTRODUCTION: Clinical outcomes of human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus disease 2019 (COVID-19). Epidemiological studies have identified three risk factors for severe disease: being male, being elderly, and having other medical conditions. However, interindividual clinical variability remains huge in each demographic category. Discovering the root cause and detailed molecular, cellular, and tissue- and body-level mechanisms underlying life-threatening COVID-19 is of the utmost biological and medical importance.


RATIONALE: We established the COVID Human Genetic Effort (www.covidhge.com) to test

the general hypothesis that life-threatening COVID-19 in some or most patients may be caused by monogenic inborn errors of immunity to SARS-CoV-2 with incomplete or complete penetrance. We sequenced the exome or genome of 659 patients of various ancestries with life-threatening COVID-19 pneumonia and 534 subjects with asymptomatic or benign infection. We tested the specific hypothesis that inborn errors of Toll-like receptor 3 (TLR3)- and interferon regulatory factor 7 (IRF7)-dependent type I interferon (IFN) immunity that underlie life-threatening influenza pneumonia also underlie life-threatening COVID-19 pneumonia. We considered three loci identified as mutated in patients with life-threatening influenza: *TLR3*, *IRF7*, and *IRF9*. We also con-

sidered 10 loci mutated in patients with other viral illnesses but directly connected to the three core genes conferring influenza susceptibility: *TICAM1/TRIF*, *UNC93B1*, *TRAF3*, *TBK1*, *IRF3*, and *NEMO/IKBKG* from the TLR3-dependent type I IFN induction pathway, and *IFNAR1*, *IFNAR2*, *STAT1*, and *STAT2* from the IRF7- and IRF9-dependent type I IFN amplification pathway. Finally, we considered various modes of inheritance at these 13 loci.

RESULTS: We found an enrichment in variants predicted to be loss-of-function (pLOF), with a minor allele frequency <0.001, at the 13 candidate loci in the 659 patients with life-threatening COVID-19 pneumonia relative to the 534 subjects with asymptomatic or benign infection ($P = 0.01$). Experimental tests for all 118 rare nonsynonymous variants (including both pLOF and other variants) of these 13 genes found in patients with critical disease identified 23 patients (3.5%), aged 17 to 77 years, carrying 24 deleterious variants of eight genes. These variants underlie autosomal-recessive (AR) deficiencies (*IRF7* and *IFNAR1*) and autosomal-dominant (AD) deficiencies (*TLR3*, *UNC93B1*, *TICAM1*, *TBK1*, *IRF3*, *IRF7*, *IFNAR1*, and *IFNAR2*) in four and 19 patients, respectively. These patients had never been hospitalized for other life-threatening viral illness. Plasmacytoid dendritic cells from IRF7-deficient patients produced no type I IFN on infection with SARS-CoV-2, and *TLR3*^{-/-}, *TLR3*^{+/-}, *IRF7*^{-/-}, and *IFNAR1*^{-/-} fibroblasts were susceptible to SARS-CoV-2 infection in vitro.

CONCLUSION: At least 3.5% of patients with life-threatening COVID-19 pneumonia had known (AR *IRF7* and *IFNAR1* deficiencies or AD *TLR3*, *TICAM1*, *TBK1*, and *IRF3* deficiencies) or new (AD *UNC93B1*, *IRF7*, *IFNAR1*, and *IFNAR2* deficiencies) genetic defects at eight of the 13 candidate loci involved in the TLR3- and IRF7-dependent induction and amplification of type I IFNs. This discovery reveals essential roles for both the double-stranded RNA sensor TLR3 and type I IFN cell-intrinsic immunity in the control of SARS-CoV-2 infection. Type I IFN administration may be of therapeutic benefit in selected patients, at least early in the course of SARS-CoV-2 infection. ■



Inborn errors of TLR3- and IRF7-dependent type I IFN production and amplification underlie life-threatening COVID-19 pneumonia. Molecules in red are encoded by core genes, deleterious variants of which underlie critical influenza pneumonia with incomplete penetrance, and deleterious variants of genes encoding biochemically related molecules in blue underlie other viral illnesses. Molecules represented in bold are encoded by genes with variants that also underlie critical COVID-19 pneumonia.

The full author list and the list of affiliations is available in the full article online.
Corresponding author: Jean-Laurent Casanova (casanova@rockefeller.edu)
This is an open-access article distributed under the terms of the Creative Commons Attribution license (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cite this article as Q. Zhang *et al.*, *Science* 370, eabd4570 (2020). DOI: 10.1126/science.abd4570

READ THE FULL ARTICLE AT
<https://doi.org/10.1126/science.abd4570>

RESEARCH ARTICLE

CORONAVIRUS

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Qian Zhang¹, Paul Bastard^{2,3*}, Zhiyong Liu^{1*}, Jérémie Le Pen^{4*}, Marcela Moncada-Velaz^{1*}, Jie Chen^{1*}, Masato Ogishi^{1*}, Ira K. D. Sabli^{5*}, Stephanie Hodeib^{5*}, Cecilia Korol^{2*}, Jérémie Rosain^{2,3*}, Kaya Bilguvar^{6*}, Junqiang Ye^{7*}, Alexandre Bolze^{8*}, Benedetta Bigio^{1*}, Rui Yang^{1*}, Andrés Augusto Arias^{1,9,10*}, Qinhu Zhou^{1*}, Yu Zhang^{11,12*}, Fanny Onodji¹³, Sarantis Korniotis¹³, Léa Karpf¹³, Quentin Philippot^{2,3}, Marwa Chbihi^{2,3}, Lucie Bonnet-Madin¹⁴, Karim Dorgham¹⁵, Nikaia Smith¹⁶, William M. Schneider⁴, Brandon S. Razoooky⁴, Hans-Heinrich Hoffmann⁴, Eleftherios Michailidis⁴, Leen Moens¹⁷, Ji Eun Han¹, Lazaro Lorenzo^{2,3}, Lucy Bizien^{2,3}, Philip Meade¹⁸, Anna-Lena Neehus^{2,3}, Aileen Camille Ugurbil¹, Aurélien Corneau¹⁹, Gaspard Kerner^{2,3}, Peng Zhang¹, Franck Rapaport¹, Yoann Seeleuthner^{2,3}, Jeremy Manry^{2,3}, Cecile Masson²⁰, Yohann Schmitt²⁰, Agatha Schlüter²¹, Tom Le Voyer^{2,3}, Taushif Khan²², Juan Li¹, Jacques Fellay^{23,24,25}, Lucie Roussel²⁶, Mohammad Shahrooei^{27,28}, Mohammed F. Alosaimi²⁹, Davood Mansouri^{30,31,32}, Haya Al-Saud³³, Fahd Al-Mulla³⁴, Feras Almourfi³³, Saleh Zaid Al-Muhsen³⁵, Fahad Alshohime²⁹, Saeed Al Turki^{36,37}, Rana Hasanato²⁹, Diederik van de Beek³⁸, Andrea Biondi³⁹, Laura Rachele Bettini³⁹, Mariella D'Angio³⁹, Paolo Bonfanti⁴⁰, Luisa Imberti⁴¹, Alessandra Sottini⁴¹, Simone Paghera⁴¹, Eugenia Quiros-Roldan⁴², Camillo Rossi⁴³, Andrew J. Oler⁴⁴, Miranda F. Tompkins⁴⁵, Camille Alba⁴⁵, Isabelle Vandernoot⁴⁶, Jean-Christophe Goffard⁴⁷, Guillaume Smits⁴⁶, Isabelle Migeotte⁴⁸, Filomeen Haerynck⁴⁹, Pere Soler-Palacin⁵⁰, Andrea Martin-Nalda⁵⁰, Roger Colobran⁵¹, Pierre-Emmanuel Morange⁵², Sevgi Keles⁵³, Fatma Çölkesen⁵⁴, Tayfun Ozcelik⁵⁵, Kadriye Kart Yasar⁵⁶, Sevtaç Senoglu⁵⁶, Şemsi Nur Karabela⁵⁶, Carlos Rodríguez-Gallego^{57,58}, Giuseppe Novelli⁵⁹, Sami Hraiech⁶⁰, Yacine Tandjaoui-Lambiotte^{61,62}, Xavier Duval^{63,64}, Cédric Laouénan^{63,64,65}, COVID-STORM Clinicians†, COVID Clinicians†, Imagine COVID Group†, French COVID Cohort Study Group†, CoV-Contact Cohort†, Amsterdam UMC Covid-19 Biobank†, COVID Human Genetic Effort†, NIAID-USUHS/TAGC COVID Immunity Group†, Andrew L. Snow⁶⁶, Clifton L. Dalgard^{45,67}, Joshua D. Milner⁶⁸, Donald C. Vinh²⁶, Trine H. Mogensen^{69,70}, Nico Marr^{22,71}, Andrés N. Spaan^{1,72}, Bertrand Boisson^{1,2,3}, Stéphanie Boisson-Dupuis^{1,2,3}, Jacinta Bustamante^{1,2,3,73}, Anne Puel^{1,2,3}, Michael J. Ciancanelli^{1,74}, Isabelle Meyts^{17,75}, Tom Maniatis^{7,76}, Vassili Soumelis^{13,77}, Ali Amara¹⁴, Michel Nussenzweig^{78,79}, Adolfo García-Sastre^{18,80,81,82}, Florian Kramer¹⁸, Aurora Pujol²¹, Darragh Duffy¹⁶, Richard P. Lifton^{83,84,85}†, Shen-Ying Zhang^{1,2,3}†, Guy Gorochov¹⁵†, Vivien Béziat^{1,2,3}†, Emmanuelle Jouanguy^{1,2,3}†, Vanessa Sancho-Shimizu⁵†, Charles M. Rice⁴†, Laurent Abel^{1,2,3}†, Luigi D. Notarangelo^{11,12}§, Aurélie Cobat^{1,2,3}§, Helen C. Su^{11,12}§, Jean-Laurent Casanova^{1,2,3,79,86}§¶

Clinical outcome upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from silent infection to lethal coronavirus disease 2019 (COVID-19). We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern Toll-like receptor 3 (TLR3)- and interferon regulatory factor 7 (IRF7)-dependent type I interferon (IFN) immunity to influenza virus in 659 patients with life-threatening COVID-19 pneumonia relative to 534 subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, we experimentally defined LOF variants underlying autosomal-recessive or autosomal-dominant deficiencies in 23 patients (3.5%) 17 to 77 years of age. We show that human fibroblasts with mutations affecting this circuit are vulnerable to SARS-CoV-2. Inborn errors of TLR3- and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already claimed at least 1 million lives, has been detected in at least 20 million people, and has probably infected at least another 200 million. The clinical manifestations range from silent infection to lethal disease, with an infection fatality rate of 0.1 to 0.9%. Three epidemiological factors increase the risk of severity: (i) increasing age, decade by decade, after the age of 50, (ii) being male,

and (iii) having various underlying medical conditions (1). However, even taking these factors into account, there is immense inter-individual clinical variability in each demographic category considered. Following on from our human genetic studies of other severe infectious diseases (2, 3), we established the COVID Human Genetic Effort (<https://www.covidhge.com>) to test the general hypothesis that in some patients, life-threatening coronavirus disease 2019 (COVID-19) may be

caused by monogenic inborn errors of immunity to SARS-CoV-2 with incomplete or complete penetrance (4). We enrolled 659 patients (74.5% men and 25.5% women, 13.9% of whom died) of various ancestries between 1 month and 99 years of age (Fig. 1A). These patients were hospitalized for life-threatening pneumonia caused by SARS-CoV-2 (critical COVID-19). We sequenced their whole genome ($N = 364$) or exome ($N = 295$), and principal component analysis (PCA) on these data confirmed their ancestries (Fig. 1B).

Candidate variants at 13 human loci that govern immunity to influenza virus

We first tested the specific hypothesis that inborn errors of Toll-like receptor 3 (TLR3)- and interferon regulatory factor 7 (IRF7)-dependent type I interferon (IFN) immunity, which underlie life-threatening influenza pneumonia, may also underlie life-threatening COVID-19 pneumonia (5) (Fig. 2). We considered three loci previously shown to be mutated in patients with critical influenza pneumonia: *TLR3* (6), *IRF7* (7), and *IRF9* (8). We also considered 10 loci mutated in patients with other viral illnesses but directly connected to the three core genes conferring influenza susceptibility: *TICAMI/TRIF* (9), *UNC93B1* (10), *TRAF3* (11), *TBK1* (12), *IRF3* (13), and *NEMO/IKBKG* (14) in the TLR3-dependent type I IFN induction pathway, and *IFNARI* (15), *IFNAR2* (16), *STAT1* (17), and *STAT2* (18) in the IRF7- and IRF9-dependent type I IFN amplification pathway. We collected both monoallelic and biallelic nonsynonymous variants with a minor allele frequency (MAF) <0.001 at all 13 loci. Twelve of the 13 candidate loci are autosomal, whereas *NEMO* is X-linked. For the latter gene, we considered only a recessive model (19). Autosomal-dominant (AD) inheritance has not been proven for six of the 12 autosomal loci (*UNC93B1*, *IRF7*, *IFNARI*, *IFNAR2*, *STAT2*, and *IRF9*). Nevertheless, we considered heterozygous variants because none of the patients enrolled had been hospitalized for critical viral infections before COVID-19, raising the possibility that any underlying genetic defects that they might have display a lower penetrance for influenza and other viral illnesses than for COVID-19, which is triggered by a more virulent virus.

Enrichment of variants predicted to be LOF at the influenza susceptibility loci

We found four unrelated patients with biallelic variants of *IRF7* or *IFNARI* (Table 1 and table S1). We also found 113 patients carrying 113 monoallelic variants at 12 loci: *TLR3* ($N = 7$ patients/7 variants), *UNC93B1* ($N = 10/9$), *TICAMI* ($N = 17/15$), *TRAF3* ($N = 6/6$), *TBK1* ($N = 12/11$), *IRF3* ($N = 5/5$), *IRF7* ($N = 20/13$), *IFNARI* ($N = 14/13$), *IFNAR2* ($N = 17/15$), *STAT1* ($N = 4/4$), *STAT2* ($N = 11/11$), and *IRF9* ($N = 4/4$). We detected no copy number variation




Fig. 1. Demographic and genetic data for the COVID-19 cohort. (A) Age and sex distribution of patients with life-threatening COVID-19. (B) PCA of patient (with or without LOF variants in the 13 candidate genes) and control cohorts (patients with mild or asymptomatic disease and individuals from the 1000 Genomes Project).

¹St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA. ²Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France. ³University of Paris, Imagine Institute, Paris, France. ⁴Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA. ⁵Department of Paediatric Infectious Diseases & Virology, Imperial College London, London, UK. ⁶Yale Center for Genome Analysis and Department of Genetics, Yale School of Medicine, New Haven, CT, USA. ⁷Zukerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA. ⁸Helix, San Mateo, CA, USA. ⁹Primary Immunodeficiencies Group, University of Antioquia UdeA, Medellin, Colombia. ¹⁰School of Microbiology, University of Antioquia UdeA, Medellin, Colombia. ¹¹Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA. ¹²NIAID Clinical Genomics Program, NIH, Bethesda, MD, USA. ¹³Université de Paris, Institut de Recherche Saint-Louis, INSERM U976, Hôpital Saint-Louis, Paris, France. ¹⁴Laboratory of Genomes & Cell Biology of Disease, INSERM U944, CNRS UMR 7212, Université de Paris, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, Paris, France. ¹⁵Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses-Paris (CIMI PARIS), Assistance Publique-Hôpitaux de Paris (AP-HP) Hôpital Pitié-Salpêtrière, Paris, France. ¹⁶Translational Immunology Lab, Institut Pasteur, Paris, France. ¹⁷Laboratory for Inborn Errors of Immunity, Department of Microbiology, Immunology and Transplantation, Department of Pediatrics, University Hospitals Leuven, KU Leuven, Leuven, Belgium. ¹⁸Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁹Sorbonne Université, UMS037, PASS, Plateforme de Cytométrie de la Pitié-Salpêtrière CyPS, Paris, France. ²⁰Bioinformatics Platform, Structure Fédérative de Recherche Necker, INSERM UMR1163, Université de Paris, Imagine Institute, Paris, France. ²¹Neurometabolic Diseases Laboratory, IDIBELL-Hospital Duran i Reynals, CIBERER U759, and Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain. ²²Department of Immunology, Research Branch, Sidra Medicine, Doha, Qatar. ²³School of Life sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. ²⁴Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. ²⁵Swiss Institute of Bioinformatics, Lausanne, Switzerland. ²⁶Infectious Disease Susceptibility Program, Research Institute, McGill University Health Centre, Montréal, Québec, Canada. ²⁷Specialized Immunology Laboratory of Dr. Shahrooei, Sina Medical Complex, Ahvaz, Iran. ²⁸Department of Microbiology and Immunology, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium. ²⁹Department of Pathology and Laboratory Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia. ³⁰Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³¹The Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti, University of Medical Sciences, Tehran, Iran. ³²Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti, Iran. ³³National Center of Genomics Technology, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia. ³⁴Dasman Diabetes Institute, Department of Genetics and Bioinformatics, Kuwait. ³⁵Immunology Research Laboratory, Department of Pediatrics, College of Medicine and King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia. ³⁶Translational Pathology, Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Misery of National Guard Health Affairs, Riyadh, Saudi Arabia. ³⁷Cancer & Blood Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. ³⁸Amsterdam UMC, Department of Neurology, Amsterdam Neuroscience, Amsterdam, Netherlands. ³⁹Pediatric Department and Centro Tettamanti-European Reference Network PaedCan, EuroBloodNet, MetabERN-University of Milano-Bicocca-Fondazione MBBM-Ospedale, San Gerardo, Monza, Italy. ⁴⁰Department of Infectious Diseases, San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy. ⁴¹CREA Laboratory, Diagnostic Laboratory, ASST Spedali Civili di Brescia, Brescia, Italy. ⁴²Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia, Brescia, Italy. ⁴³Chief Medical Officer, ASST Spedali Civili di Brescia, Brescia, Italy. ⁴⁴Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, NIAID, NIH, Bethesda, MD, USA. ⁴⁵PRIMER, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. ⁴⁶Center of Human Genetics, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. ⁴⁷Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. ⁴⁸Fonds de la Recherche Scientifique (FNRS) and Center of Human Genetics, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. ⁴⁹Department of Paediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent (CPiG), PID Research Lab, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Ghent, Belgium. ⁵⁰Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain. ⁵¹Immunology Division, Genetics Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, UAB, Barcelona, Catalonia, Spain. ⁵²Aix Marseille Univ, INSERM, INRAE, C2VN, CHU Timone, Marseille, France. ⁵³Necmettin Erbakan University, Meram Medical Faculty, Division of Pediatric Allergy and Immunology, Konya, Turkey. ⁵⁴Department of Infectious Diseases and Clinical Microbiology, Konya Training and Research Hospital, Konya, Turkey. ⁵⁵Department of Molecular Biology and Genetics, Bilkent University, Bilkent-Ankara, Turkey. ⁵⁶Departments of Infectious Diseases and Clinical Microbiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. ⁵⁷Department of Immunology, Hospital Universitario de G.C. Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain. ⁵⁸University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain. ⁵⁹Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy. ⁶⁰Intensive Care Unit, AP-HM, Marseille, France. ⁶¹Avicenne Hospital Intensive Care Unit, APHP, Bobigny, INSERM U1272 Hypoxia & Lung, Paris, France. ⁶²PH Réanimation CHU Avicenne, Bobigny, INSERM U1272 Hypoxie & Poumon, Paris, France. ⁶³Université de Paris, IAME UMR-S 1137, INSERM, Paris, France. ⁶⁴Inserm CIC 1425, Paris, France. ⁶⁵AP-HP, Département Épidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat, Paris, France. ⁶⁶Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. ⁶⁷Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. ⁶⁸Division of Pediatric Allergy, Immunology and Rheumatology, Columbia University, New York, USA. ⁶⁹Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark. ⁷⁰Department of Biomedicine, Aarhus University, Aarhus, Denmark. ⁷¹College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar. ⁷²Department of Medical Microbiology, Utrecht UMC, Utrecht, Netherlands. ⁷³Study Center for Primary Immunodeficiencies, Necker Hospital for Sick Children, Paris, France. ⁷⁴Turnstone Biologics, New York, NY, USA. ⁷⁵Department of Pediatrics, University Hospitals Leuven, KU Leuven, Leuven, Belgium. ⁷⁶New York Genome Center, New York, NY, USA. ⁷⁷AP-HP, Hôpital Saint-Louis, Laboratoire d'Immunologie, Paris, France. ⁷⁸Laboratory of Molecular Immunology, Rockefeller University, New York, NY, USA. ⁷⁹Howard Hughes Medical Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁸⁰Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁸¹Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁸²The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁸³Laboratory of Genetics and Genomics, The Rockefeller University, New York, NY, USA. ⁸⁴Department of Genetics, Yale University School of Medicine, New Haven, CT, USA. ⁸⁵Yale Center for Genome Analysis, Yale School of Medicine, New Haven, CT, USA. ⁸⁶Pediatric Hematology and Immunology Unit, Necker Hospital for Sick Children, AP-HP, Paris, France.

*These authors contributed equally to this work.

†All collaborators and their affiliations appear at the end of this paper.

‡These authors contributed equally to this work.

§These authors contributed equally to this work.

¶Corresponding author. Email: casanova@rockefeller.edu

for these 13 genes. Unexpectedly, one of these variants has been reported in patients with life-threatening influenza pneumonia (*TLR3* p.Pro554Ser) (6, 20) and another was shown to be both deleterious and dominant-negative

(*IFNAR1* p.Pro335del) (21). Nine of the 118 biallelic or monoallelic variants were predicted to be LOF (pLOF), whereas the remaining 109 were missense or in-frame indels (table S1). In a sample of 534 controls with asymptomatic

or mild SARS-CoV-2 infection, we found only one heterozygous pLOF variation with a MAF <0.001 at the 13 loci (*IRF7* p.Leu99fs). A PCA-adjusted burden test on the 12 autosomal loci revealed significant enrichment in pLOF variants in patients relative to controls [$P = 0.01$; odds ratio (OR) = 8.28; 95% confidence interval (CI) = 1.04 to 65.64] under an AD mode of inheritance. The same analysis performed on synonymous variants with a MAF <0.001 was not significant ($P = 0.19$), indicating that our ethnicity-adjusted burden test was well calibrated.

Experimentally deleterious alleles at the influenza susceptibility loci in 3.5% of patients

We tested these 118 variants experimentally in ad hoc overexpression systems. We found that 24 variants of eight genes were deleterious (including all the pLOF variants) because they were loss-of-expression, LOF, or severely hypomorphic: *TLR3* ($N = 4$ variants), *UNC93B1* ($N = 1$), *TICAM1* ($N = 3$), *TBK1* ($N = 2$), *IRF3* ($N = 2$), *IRF7* ($N = 8$), *IFNAR1* ($N = 3$), and *IFNAR2* ($N = 1$) (table S1, Fig. 3, and figs. S1 to S8). Consistently, heterozygous LOF variants of *IRF3* and *IRF7* were reported in single patients with life-threatening influenza pneumonia (22, 23). The remaining 94 variants were biochemically neutral. Twenty-three patients carried these 24 deleterious variants, resulting in four autosomal-recessive (AR) deficiencies (homozygosity or compound heterozygosity




Fig. 2. Illustration of TLR3- and IRF7-dependent type I IFN production and amplification circuit. Molecules in red are encoded by core genes, deleterious variants of which underlie critical influenza pneumonia with incomplete penetrance; deleterious variants of genes encoding biochemically related molecules in blue underlie other viral illnesses. Type I IFNs also induce themselves. ISGs, interferon-stimulated genes.

Table 1. Disease-causing variants identified in patients with life-threatening COVID-19.

Gene	Inheritance	Genetic form	Genotype	Gender	Age [years]	Ancestry/residence	Outcome
<i>TLR3</i>	AD	Known	p.Ser339fs/WT	M	40	Spain	Survived
<i>TLR3</i>	AD	Known	p.Pro554Ser/WT	M	68	Italy	Survived
<i>TLR3</i>	AD	Known	p.Trp769*/WT	M	77	Italy	Survived
<i>TLR3</i>	AD	Known	p.Met870Val/WT	M	56	Colombia/Spain	Survived
<i>UNC93B1</i>	AD	New	p.Glu96*/WT	M	48	Venezuela/Spain	Survived
<i>TICAM1</i>	AD	Known	p.Thr41le/WT	M	49	Italy	Survived
<i>TICAM1</i>	AD	Known	p.Ser60Cys/WT	F	61	Vietnam/France	Survived
<i>TICAM1</i>	AD	Known	p.Gln392Lys/WT	F	71	Italy	Deceased
<i>TBK1</i>	AD	Known	p.Phe24Ser/WT	F	46	Venezuela/Spain	Survived
<i>TBK1</i>	AD	Known	p.Arg308*/WT	M	17	Turkey	Survived
<i>IRF3</i>	AD	Known	p.Glu49del/WT	F	23	Bolivia/Spain	Survived
<i>IRF3</i>	AD	Known	p.Asn146Lys/WT	F	60	Italy	Survived
<i>IRF7</i>	AR	Known	p.Pro364fs/p.Pro364fs	F	49	Italy/Belgium	Survived
<i>IRF7</i>	AR	Known	p.Met371Val/p.Asp117Asn	M	50	Turkey	Survived
<i>IRF7</i>	AD	New	p.Arg7fs/WT	M	60	Italy	Survived
<i>IRF7</i>	AD	New	p.Gln185*/WT	M	44	France	Survived
<i>IRF7</i>	AD	New	p.Pro246fs/WT	M	41	Spain	Survived
<i>IRF7</i>	AD	New	p.Arg369Gln/WT	M	69	Italy	Survived
<i>IRF7</i>	AD	New	p.Phe95Ser/WT	M	37	Turkey	Survived
<i>IFNAR1</i>	AR	Known	p.Trp73Cys/Trp73Cys	M	38	Turkey	Survived
<i>IFNAR1</i>	AR	Known	p.Ser422Arg/Ser422Arg	M	26	Pakistan/Saudi Arabia	Deceased
<i>IFNAR1</i>	AD	New	p.Pro335del/WT	F	23	China/Italy	Survived
<i>IFNAR2</i>	AD	New	p.Glu140fs/WT	F	54	Belgium	Survived




Fig. 3. Impact of *TLR3*, *TICAM1*, *TBK1*, *IRF3*, *IRF7*, *IFNAR1*, and *IFNAR2* variants on type I IFN signaling.

(A) *TLR3*-deficient P2.1 fibrosarcoma cells were stably transfected with plasmids expressing WT or mutant forms of *TLR3*, and *IFNL1* mRNA levels were determined by reverse transcription quantitative PCR. *IFNL1* mRNA levels were expressed relative to the housekeeping gene *GUS* and then normalized. *IFNL1* was undetectable in unstimulated cells. The differences between variants and WT were tested using one-way ANOVA ($*P < 0.05$). (B) *TICAM1*-deficient SV40-Fib cells were transiently transfected with WT or mutant forms of *TICAM1*, together with an IFN- β luciferase reporter and a constitutively expressed reporter. Normalized luciferase induction was measured 24 hours after transfection. The differences between variants and WT were tested using one-way ANOVA ($*P < 0.05$). (C) HEK293T cells were transiently transfected with WT and mutant forms of *TBK1*, together with an IFN- β luciferase reporter and a constitutively expressed reporter. Normalized luciferase activity was measured 24 hours after transfection. The differences between variants and WT were tested using one-way ANOVA ($*P < 0.05$). (D) *IRF3*-deficient HEK293T cells were transiently transfected with WT and mutant forms of *IRF3*, together with an IFN- β

luciferase reporter and a constitutively expressed reporter. Cells were either left untreated or infected with Sendai virus for 24 hours before the normalized measurement of luciferase activity. The differences between variants and WT were evaluated using two-way ANOVA ($*P < 0.05$). (E) HEK293T cells were transiently transfected with WT and mutant forms of *IRF7*, together with an IFN- β luciferase reporter and a constitutively expressed reporter. Cells were either left untreated or infected with Sendai virus for 24 hours before the normalized measurement of luciferase activity. The differences between variants and WT were tested using two-way ANOVA ($*P < 0.05$). (F and G) *IFNAR1*- or *IFNAR2*-deficient SV40-Fib cells were transiently transfected with WT or mutant forms of *IFNAR1* for 36 hours, and either left untreated or stimulated with IFN- $\alpha 2$ or IFN- γ . Fluorescence-activated cell sorting (FACS) staining with anti-p-STAT1 antibody and the z-score of the MFI were assessed. Asterisks indicate variants with MFI $< 50\%$ of WT. Variants in red were identified in COVID-19 patients. Variants in blue are known deleterious variants and served as negative controls. EV, empty vector; LT, lipofectamine. Three technical repeats were performed for (A) to (E). Means and SD are shown in the columns and horizontal bars when appropriate.




Fig. 4. Type I IFN responses in patient cells defective for IRF7. (A) Levels of the IRF7 protein in PHA-T cells from two patients with AR IRF7 deficiency (P1 and P3), one patient with AD IRF7 deficiency (P2), and four healthy donors (C1 to C4). Cells were either left untreated or stimulated with IFN- α 2 for 24 hours, and protein levels were measured by Western blotting. MX1 was used as a positive control for IFN- α 2 treatment. (B) pDCs isolated from an AR IRF7-deficient patient (P1) and a healthy donor (C1) were either left untreated or

infected with influenza A virus (IAV) or SARS-CoV-2, and RNA-seq was performed. Genes with expression >2.5-fold higher or lower in C1 after infection are plotted as the fold change in expression. Red dots are type I IFN genes; blue dots are type III IFN genes. (C) pDCs isolated from healthy donor C and IRF7-deficient patient (P1) were either left untreated (Medium) or infected with IAV or SARS-CoV-2, and the production of IFN- α 2 and IFN- λ 1 was measured by CBA and ELISA, respectively, on the supernatant. ND, not detected.

for IRF7; homozygosity for *IFNAR1*) and 19 AD deficiencies. These 23 patients did not carry candidate variants at the other 417 loci known to underlie inborn errors of immunity (table S2) (24–26). These findings suggest that at least 23 (3.5%) unrelated patients of the 659 patients tested suffered from a deficiency at one of eight loci among the 13 tested: four patients with a known AR disorder (*IRF7* or *IFNAR1*) (7, 15), 11 with a known AD disorder (*TLR3*, *TICAM1*, *TBKI*, or *IRF3*) (6, 9, 12, 13, 20), and eight with a previously unknown AD genetic disorder (*UNC93B1*, *IRF7*, *IFNAR1*, or *IFNAR2*).

Impaired TLR3- and IRF7-dependent type I immunity in patient cells in vitro

We tested cells from patients with selected genotypes and showed that PHA-driven T cell blasts (PHA-T cells) from patients with AR or AD IRF7 deficiency had low levels of IRF7 expression (Fig. 4A). We then isolated circulating plasmacytoid dendritic cells (pDCs) from a patient with AR IRF7 deficiency (fig. S9A) (7). These cells were present in normal proportions (fig. S9B), but they did not produce any detectable type I or III IFNs in response to SARS-CoV-2, as analyzed by cytometric bead

array (CBA), enzyme-linked immunosorbent assay (ELISA), and RNA sequencing (RNA-seq) (Fig. 4, B and C). We also showed that PHA-T cells from a patient with AR IFN- α / β receptor 1 (*IFNAR1*) deficiency had impaired *IFNAR1* expression and responses to IFN- α 2 or IFN- β , and that the patient's SV40-transformed fibroblast (SV40-Fib) cells did not respond to IFN- α 2 or IFN- β (Fig. 5). We then infected *TLR3*^{-/-}, *TLR3*^{+/-}, *IRF7*^{-/-} SV40-Fib cells, and *IRF7*^{-/-} SV40-Fib cells rescued with wild-type (WT) IRF7; *IFNAR1*^{-/-} SV40-Fib cells, and *IFNAR1*^{-/-} SV40-Fib cells rescued with WT




Fig. 5. Type I IFN responses in patient cells defective for IFNAR1. (A) FACS staining of IFNAR1 on the surface of PHA-T cells from a patient with AR IFNAR1 deficiency (P5) and healthy donors (C1 and C2). (B) PHA-T cells and SV40-Fib from a patient with AR IFNAR1 deficiency (P5) and a healthy donor (C3) were stimulated with IFN- α 2 or IFN- β , and p-STAT1 levels were determined by FACS. Interleukin-27 stimulation served as a positive control on PHA-T cells, whereas IFN- γ stimulation served as a positive control on SV40-Fib cells.

IFNAR1, all of which were previously transduced with angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2). SARS-CoV-2 infection levels were higher in mutant cells than in cells from healthy donors, and transduction of WT *IRF7* or *IFNAR1* rescued their defects (Fig. 6). Collectively, these findings showed that AR *IRF7* deficiency impaired the production of type I IFN by pDCs stimulated with SARS-CoV-2, whereas AR and AD deficiencies of TLR3 or AR deficiency of IFNAR1 impaired fibroblast-intrinsic type I IFN immunity to SARS-CoV2. They also suggest that heterozygosity for LOF variations at the other five mutated loci also underlie life-threatening COVID-19.

Impaired production of type I IFNs in patients in vivo

We tested whether these genotypes impaired the production of type I IFN in vivo during the course of SARS-CoV-2 infection. We measured the levels of the 13 types of IFN- α in the blood of patients during the acute phase of COVID-19. We found that 10 of the 23 patients with mutations for whom samples were available (one with AR *IRF7* deficiency, four with AD *IRF7* deficiency, one with AD TLR3 deficiency, two with AD *TBK1* deficiency, one with AR *IFNAR1* deficiency, and one with AD *TICAM1* deficiency) had serum IFN- α levels <1 pg/ml

(Fig. 7). By contrast, previously published cohorts of patients hospitalized with unexplained, severe COVID-19 had various serum IFN- α levels, significantly higher than our 10 patients [one-way analysis of variance (ANOVA), $P = 1.4 \times 10^{-7}$; Fig. 7] (27, 28). Another 29 patients from our cohort displaying auto-antibodies (auto-Abs) against type I IFNs, reported in an accompanying paper, had undetectable levels of serum IFN- α (29). Moreover, none of the 23 patients with LOF mutations of the eight genes had detectable auto-Abs against type I IFNs (29), strongly suggesting that the two mechanisms of disease are similar but independent. Excluding patients with auto-Abs against type I IFN from the burden test of pLOF variants at the 12 autosomal loci strengthened the association signal ($P = 0.007$; OR = 8.97; 95% CI = 1.13 to 71.09).

Inborn errors of TLR3- and IRF7-dependent type I immunity underlie critical COVID-19

Collectively, our data suggest that at least 23 of the 659 patients with life-threatening COVID-19 pneumonia studied had known (six disorders) or new (four disorders) genetic defects at eight loci involved in the TLR3- and IRF7-dependent induction and amplification of type I IFNs. This discovery reveals the essential role of both the double-stranded RNA sensor TLR3 and type I IFN cell-intrinsic immunity in the

control of SARS-CoV-2 infection in the lungs, consistent with their previously documented roles in pulmonary immunity to influenza virus (5–8). These genotypes were silent until infection with SARS-CoV-2. The most thought-provoking examples are the AR deficiencies of *IRF7* and *IFNAR1*. AR *IRF7* deficiency was diagnosed in two individuals aged 49 and 50 years, and AR *IFNAR1* deficiency was diagnosed in two individuals aged 26 and 38 years, and none of the four patients had a prior history of life-threatening infections (Table 1). One patient with *IRF7* deficiency was tested and was seropositive for several common viruses, including various influenza A and B viruses (figs. S10 and S11). These genetic defects therefore display incomplete penetrance for influenza respiratory distress and only manifested clinically upon infection with the more virulent SARS-CoV-2.

Conclusion

The AR form of *IFNAR1* deficiency highlights the importance of type I IFN production relative to type III IFN production, which is also impaired by defects of TLR3, *IRF7*, and *IRF9* (5). This conclusion is also supported by our accompanying report of neutralizing auto-Abs against type I IFNs, but not type III IFNs, in other patients with life-threatening COVID-19 pneumonia (29). Inborn errors of TLR3- and




Fig. 6. Cell-intrinsic type I IFN response to SARS-CoV-2. SV40-Fib cells of TLR3^{-/-}, TLR3^{+/-}, IRF7^{-/-}, and IRF7^{-/-} SV40-Fib cells rescued with WT IRF7; IFNAR1^{-/-} SV40-Fib cells, and IFNAR1^{-/-} SV40-Fib cells rescued with WT IFNAR1 were transduced with ACE2 and TMPRSS2 and then either left untreated or treated with IFN- β for 4 hours. Cells were then infected with SARS-CoV-2 (MOI = 0.5). After staining, ACE2 and viral S-protein levels were measured by high-content microscopy with gating on ACE2⁺ cells. IRF7-deficient SV40-Fib cells were previously transduced with either WT IRF7 or negative control (Luc). IFNAR1-deficient cells were previously transduced with either WT IFNAR1 or empty vector (EV).

IRF7-dependent type I IFN immunity at eight loci were found in as many as 23 patients (3.5%) of various ages (17 to 77 years) and ancestries (various nationalities from Asia, Europe, Latin America, and the Middle East) and in patients of both sexes (Table 1). Our findings suggest that there may be mutations in other type I IFN-related genes in other patients with life-threatening COVID-19 pneumonia. They also suggest that the administration of type I IFN may be of therapeutic benefit in selected patients, at least early in the course of SARS-CoV-2 infection.

Methods

Patients

We included in this study 659 patients with life-threatening COVID-19 pneumonia, defined as patients with pneumonia who developed critical disease, whether pulmonary with mechanical ventilation (CPAP, BIPAP, intubation, hi-flow oxygen), septic shock, or with any other organ damage requiring admission to the intensive care unit. Patients who developed Kawasaki-like syndrome were excluded. The age of the patients ranged from 0.1 to 99 years, with a mean age of 51.8 years (SD 15.9 years), and 25.5% of the patients were female. As controls, we enrolled 534 individuals infected with SARS-CoV-2 based on a positive polymerase chain reaction (PCR) and/or serological test and/or the presence of typical symptoms such as anosmia or ageusia after exposure to a confirmed COVID-19 case, who remained asymptomatic or developed mild, self-healing, ambulatory disease.


Next-generation sequencing

Genomic DNA was extracted from whole blood. For the 1193 patients and controls included, the whole exome ($N = 687$) or whole genome ($N = 506$) was sequenced. We used the Genome Analysis Software Kit (GATK) (version 3.4-46 or 4) best-practice pipeline to analyze our whole-exome-sequencing data (30). We aligned the reads obtained with the human reference genome (hg19) using the maximum exact matches algorithm in Burrows-Wheeler Aligner software (31). PCR duplicates were removed with Picard tools (<http://broadinstitute.github.io/picard/>). The GATK base quality score recalibrator was applied to correct sequencing artifacts.

All of the variants were manually curated using Integrative Genomics Viewer (IGV) and confirmed to affect the main functional protein isoform by checking the protein sequence before inclusion in further analyses. The main functional protein isoforms were TLR3 (NM_003265), UNC93B1 (NM_030930.4), TICAM1 (NM_182919), TRAF3 (NM_145725.2), TBK1 (NM_013254.4), IRF3 (NM_001571), IRF7 (NM_001572.5), IFNAR1 (NM_000629.3), IFNAR2 (NM_001289125.3), STAT1 (NM_007315.4), STAT2

Fig. 7. In vivo type I IFN responses to SARS-CoV-2 infections.

Plasma levels of 13 IFN- α were measured by Simoa. Auto-Ab(+) without LOF variants indicates COVID-19 patients with neutralizing anti-IFN- α auto-Ab in our accompanying report (29). P values indicated were evaluated using one-way ANOVA.



(NM_005419.4), and IRF9 (NM_006084.5). The analysis of IKBKG was customized to unmask the duplicated region in IKBKG using a specific pipeline previously described (32). We searched the next-generation-sequencing data for deletions in the 13 genes of interest using both the HMZDelFinder (33) and CANOES (34) algorithms.

Statistical analysis

We performed an enrichment analysis on our cohort of 659 patients with life-threatening COVID-19 pneumonia and 534 SARS-CoV2-infected controls, focusing on 12 autosomal IFN-related genes. We considered variants that were pLOF with a MAF <0.001 (gnomAD version 2.1.1) after experimentally demonstrating that all of the pLOF variants seen in the cases were actually LOF. We compared the proportion of individuals carrying at least one pLOF variant of the 12 autosomal genes in cases and controls by means of logistic regression with the likelihood ratio test. We ac-

counted for the ethnic heterogeneity of the cohorts by including the first three principal components of the PCA in the logistic regression model. PC adjustment is a common and efficient strategy for accounting for different ancestries of patients and controls in the study of rare variants (35–38). We checked that our adjusted burden test was well calibrated by also performing an analysis of enrichment in rare (MAF <0.001) synonymous variants of the 12 genes. PCA was performed with Plink version 1.9 software on whole-exome- and whole-genome-sequencing data and the 1000 Genomes (1kG) Project phase 3 public database as a reference, using 27,480 exonic variants with a MAF >0.01 and a call rate >0.99. The OR was also estimated by logistic regression and adjusted for ethnic heterogeneity.

Reporter assays

Cell lines or SV40-Fib cells with known defects were transiently or stably transfected with WT, mutant variants, IFN- β - or ISRE-*firefly*

luciferase reporter, and pRL-TK-*Renilla* luciferase reporter. Reporter activity was measured with the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. *Firefly* luciferase activity was normalized against *Renilla* luciferase activity and expressed as a fold change. TRAF3-deficient human embryonic kidney (HEK) 293T cells were kindly provided by M. Romanelli (39).

pDC activation by SARS-CoV-2 and cytokine production

pDCs from an IRF7^{-/-} patient and a healthy donor matched for age and sex were cultured in the presence of medium alone, influenza virus (A/PR/8/34, 2 μ g/ml; Charles River Laboratories), or the SARS-CoV-2 primary strain 220_95 (GISAID accession ID: EPI_ISL_469284) at a multiplicity of infection (MOI) of 2. After 12 hours of culture, pDC supernatant was collected for cytokine quantification. IFN- α 2 levels were measured using CBA analysis (BD Biosciences) in accordance with the manufacturer's protocol using a 20 pg/ml detection limit. IFN- λ 1 secretion was measured in an ELISA (R&D Systems, DuoSet DY7246), in accordance with the manufacturer's instructions.

SARS-CoV-2 infection in patient SV40-Fib

To make patient-derived fibroblasts permissive to SARS-CoV-2 infection, we delivered human ACE2 and TMPRSS2 cDNA to cells by lentivirus transduction using a modified SCRPSY vector (GenBank ID: KT368137.1). SARS-CoV-2 strain USA-WA1/2020 was obtained from BEI Resources. ACE2/TMPRSS2-transduced cells were either left untreated or treated with 500 U/ml IFN- β (11415-1, PBL Assay Science) 4 hours before infection. Cells were infected with SARS-CoV-2 (MOI = 0.5) for 1 hour at 37°C. After 24 hours of infection, cells were fixed and taken out of the BSL3 for staining.

After fixation, cells were stained with SARS-CoV-2 and ACE2 primary antibodies (0.5 and 1 μ g/ml, respectively). Primary antibodies were as follows: for SARS-CoV-2, human monoclonal anti-spike-SARS-CoV-2 C121 antibody (40), and for ACE2, mouse monoclonal Alexa Fluor 488-conjugated antibody (FAB9332G-100UG, R&D Systems). Images were acquired with an ImageXpress Micro XLS microscope (Molecular Devices) using the 4 \times objective. MetaXpress software (Molecular Devices) was used to obtain single-cell mean fluorescence intensity (MFI) values.

Data analysis on single-cell MFI values was done in the R environment (version 4.0.2). ACE2/TMPRSS2-transduced cells were classified as ACE2 positive when the ACE2 log MFI was superior to the log mean MFI of mock-transduced cells plus 2.5 SDs. We excluded all wells with <150 ACE2-positive cells before SARS-CoV-2 scoring. ACE2-expressing cells were classified SARS-CoV-2 positive when the fluorescence intensity value was superior to

- Diseases, CHU de Caen, Caen, France. ²²Consorcio Hospital General Universitario, Valencia, Spain. ²³The Genetics Institute, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ²⁴Department of Urology, Nephrology, and Transplantation, APHP-SU, Sorbonne Université, INSERM U 1082, Paris, France. ²⁵Service de Médecine Intensive-Réanimation et Pneumologie, APHP Hôpital Pitié-Salpêtrière, Paris, France. ²⁶Cruces University Hospital, Bizkaia, Spain. ²⁷Paediatric Immunology and Vaccinology Unit, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland. ²⁸Hematology, Georges Pompidou Hospital, APHP, Paris, France. ²⁹Pediatric Infectious Diseases Unit, Instituto de Investigación 12 de Octubre imas12, and Hospital Universitario 12 de Octubre, Madrid, Spain. ³⁰Department of Immunology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Department of Pediatrics, Thomayer's Hospital, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. ³¹Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain. ³²Service de Pneumologie, Hôpital Bichat, APHP, Paris, France. ³³Department of Pulmonology, Ghent University Hospital, Ghent, Belgium. ³⁴Clinical Immunology Unit, Pediatric Infectious Disease Department, Faculty of Medicine and Pharmacy, Averroes University Hospital, LICIA Laboratoire d'Immunologie Clinique, d'Inflammation et d'Allergie, Hassani li University, Casablanca, Morocco. ³⁵Endocrinology Unit, APHP Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France. ³⁶Department of Children's Diseases and Pediatric Surgery, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine. ³⁷Human Genome and Stem-Cell Research Center, University of São Paulo, São Paulo, Brazil. ³⁸Hospital Insular, Las Palmas de Gran Canaria, Spain. ³⁹Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Konya State Hospital, Konya, Turkey. ⁴⁰MS Center, Spedali Civili, Brescia, Italy. ⁴¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. ⁴²Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. ⁴³Hôpital Robert Debré, Paris, France. ⁴⁴Pediatric Immuno-hematology Unit, Necker Enfants Malades Hospital, AP-HP, Paris, France. ⁴⁵Department of Infectious and Tropical Diseases, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. ⁴⁶Doctoral Health Care Center, Canarian Health System, Las Palmas de Gran Canaria, Spain. ⁴⁷Hôpital Foch, Suresnes, France. ⁴⁸Necker Hospital for Sick Children, Paris University, AP-HP, Paris, France. ⁴⁹Pasteur Institute, Paris, France. ⁵⁰McGill University Health Centre, Montreal, Canada. ⁵¹University Hospital and Research Institute "Germans Trias i Pujol," IrsiCaixa AIDS Research Institute, Uvic-UCC, Badalona, Spain. ⁵²Clinical Biochemistry, Pathology, Paediatric Neurology and Molecular Medicine Departments and Biobank, Institut de Recerca Sant Joan de Déu and CIBERER-ISCIII, Espulgues, Spain. ⁵³Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. ⁵⁴Department of Infectious Diseases and Clinical Microbiology, Konya Training and Research Hospital, Konya, Turkey. ⁵⁵Hospital Universitari Vall d'Hebron, Barcelona, Spain. ⁵⁶Pitié-Salpêtrière Hospital, Paris, France. ⁵⁷Fundació Docència i Recerca Mútua Terrassa, Barcelona, Spain; Hospital Universitari Mutua Terrassa, Universitat de Barcelona, Terrassa, Catalonia, Spain. ⁵⁸UNSW Medicine, St. Vincent's Clinical School, and Department of Thoracic Medicine, St. Vincent's Hospital Darlinghurst, Sydney, Australia. ⁵⁹CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium. ⁶⁰Pediatric Intensive Care Unit, Robert-Debré University Hospital, APHP, Paris, France. ⁶¹Sorbonne Paris Nord, Hôpital Jean Verdier, APHP, Bondy, France. ⁶²Specialized Immunology Laboratory of Dr. Shahroei, Sina Medical Complex, Ahvaz, Iran. ⁶³Centre de Génétique Humaine, CHU Besançon, Besançon, France. ⁶⁴Sorbonne Université Médecine and APHP Sorbonne Université Site Pitié-Salpêtrière, Paris, France. ⁶⁵Intensive Care Unit, Georges Pompidou Hospital, APHP, Paris, France. ⁶⁶Department of Pneumology, AZ Delta, Roeselare, Belgium. ⁶⁷Institut Jérôme Lejeune, Paris, France. ⁶⁸Department of Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. ⁶⁹Department of Chest, Faculty of Medicine, Mansoura University, Mansoura, Egypt. ⁷⁰Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. ⁷¹Faculty of Medicine, Division of Pediatric Infectious Diseases, Selcuk University, Konya, Turkey. ⁷²Division of Pediatric Infectious Diseases, Ondokuz Mayıs University, Samsun, Turkey. ⁷³Necmettin Erbakan University, Meram Medical Faculty, Division of Pediatric Allergy and Immunology, Konya, Turkey. ⁷⁴Centre Hospitalier Fleyriat, Bourg-en-Bresse, France. ⁷⁵Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. ⁷⁶Centre de Génétique, CHU Dijon, Dijon, France. ⁷⁷APHF Tenon Hospital, Paris, France. ⁷⁸Sorbonne Universités, UPMC University of Paris, Paris, France. ⁷⁹Department of Clinical Immunology, Hospital Clínico San Carlos, Madrid, Spain. ⁸⁰Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Research Unit, Hospital Universitario N.S. de Candelaria, Santa Cruz de Tenerife, Spain; Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, San Cristóbal de La Laguna, Spain. ⁸¹CHU Limoges and Inserm CIC 1435 and UMR 1092, Limoges, France. ⁸²Infectious Diseases Unit, Department of Pediatrics, Hospital Sant Joan de Déu, Barcelona, Spain; Institut de Recerca Sant Joan de Déu, Spain; Universitat de Barcelona (UB), Barcelona, Spain. ⁸³Institute of Genetics and Biophysics "Adriano Buzzati-Traverso," IGB-CNR, Naples, Italy. ⁸⁴Laboratory of Immunogenetics of Human Diseases, IdiPAZ Institute for Health Research, La Paz Hospital, Madrid, Spain. ⁸⁵Hematology, APHP, Hôpital Européen Georges Pompidou and Inserm UMR-S1140, Paris, France. ⁸⁶Hospital General Universitario and Instituto de Investigación Sanitaria "Gregorio Marañón," Madrid, Spain. ⁸⁷Bégin military Hospital, Bégin, France. ⁸⁸Pediatric Intensive Care Unit, Hospital Sant Joan de Déu, Barcelona, Spain. ⁸⁹Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. ⁹⁰Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. ⁹¹Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain. ⁹²Assistance Publique Hôpitaux de Paris, Paris, France. ⁹³Division of Allergy and Immunology, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. ⁹⁴CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST); Universitat Pompeu Fabra (UPF), Barcelona, Spain. ⁹⁵Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France. ⁹⁶Ghent University Hospital, Ghent, Belgium. ⁹⁷Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, UAE. ⁹⁸Department of Laboratory Medicine, SE14186, Huddinge, Karolinska Institutet, Stockholm, Sweden. ⁹⁹Pediatric Infectious Diseases Unit, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. ¹⁰⁰Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain. ¹⁰¹Department of Pediatric Hemato-Oncology, Jolimont Hospital; Department of Pediatric Hemato-Oncology, HUIDEF, Brussels, Belgium. ¹⁰²Intensive Care Unit, Marqués de Valdecilla Hospital, Santander, Spain. ¹⁰³Hospital del Mar, Parc de Salut Mar, Barcelona, Spain. ¹⁰⁴Department of Pediatric Pulmonology and Immunology, Ghent University Hospital, Ghent, Belgium. ¹⁰⁵Department of Intensive Care Unit, Ghent University Hospital, Ghent, Belgium. ¹⁰⁶Intensive Care Unit, APHM, Marseille, France. ¹⁰⁷CHU Lille, Lille, France. ¹⁰⁸Department of Pediatrics, Columbia University, New York, NY, USA. ¹⁰⁹Centre Hospitalier Intercommunal Poissy Saint Germain en Laye, Poissy, France. ¹¹⁰Fundació Docència i Recerca Mútua Terrassa, Terrassa, Spain. ¹¹¹Hospital Sant Joan de Déu, Kids Corona Platform, Barcelona, Spain. ¹¹²Department of Intensive Care Unit, University Hospital Antwerp, Antwerp, Belgium. ¹¹³Selcuk University, Faculty of Medicine, Chest Diseases Department, Konya, Turkey. ¹¹⁴Division of Allergy and Immunology, Balikesir Ataturk City Hospital, Balikesir, Turkey. ¹¹⁵Division of Critical Care Medicine, Selcuk University, Faculty of Medicine, Konya, Turkey. ¹¹⁶Division of Pediatric Infectious Diseases, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey. ¹¹⁷Departments of Infectious Diseases and Clinical Microbiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. ¹¹⁸Meram Medical Faculty, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. ¹¹⁹Health Sciences University, Umraniye Education and Research Hospital, Istanbul, Turkey. ¹²⁰Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, Prague, Czech Republic. ¹²¹Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Warsaw, Poland. ¹²²Oncobiologie Génétique Bioinformatique, PC Bio, CHU Besançon, Besançon, France. ¹²³Paediatric Infectious Disease Unit, Hospital Authority Infectious Disease Center, Princess Margaret Hospital, Hong Kong (Special Administrative Region), China. ¹²⁴Aix Marseille University, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France. ¹²⁵Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China. ¹²⁶National Centre for Infectious Diseases, Singapore. ¹²⁷Hospital Universitario Reina Sofía, Córdoba, Spain. ¹²⁸Imperial College, London, UK. ¹²⁹Endocrinology and Diabetes for Children, AP-HP, Bicêtre Paris-Saclay Hospital, Le Kremlin-Bicêtre, France. ¹³⁰Department of Medical Genetics, University Hospital Antwerp, Antwerp, Belgium. ¹³¹Neurology Unit, APHP Pitié-Salpêtrière Hospital, Paris University, Paris, France. ¹³²Intensive Care Unit, APHP Pitié-Salpêtrière Hospital, Paris University, Paris, France. ¹³³National Centre for Infectious Diseases; Tan Tock Seng Hospital; Yong Loo Lin School of Medicine; Lee Kong Chian School of Medicine, Singapore. ¹³⁴Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ¹³⁵Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRIITD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. ¹³⁶Hospital Sant Joan de Déu and University of Barcelona, Barcelona, Spain. ¹³⁷Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. ¹³⁸Hospital Universitari Mutua de Terrassa, Universitat de Barcelona, Barcelona, Spain. ¹³⁹IrsiCaixa AIDS Research Institute, ICREA, Uvic-UCC, Research Institute "Germans Trias i Pujol," Badalona, Spain. ¹⁴⁰Department of Laboratory, Cruces University Hospital, Barakaldo, Bizkaia, Spain. ¹⁴¹University of New South Wales, New South Wales, Australia. ¹⁴²APHF Pitié-Salpêtrière Hospital, Paris, France. ¹⁴³Aix-Marseille University, APHM, Marseille, France. ¹⁴⁴Robert Debré University, Paris, France. ¹⁴⁵APHF Cohin Hospital, Paris, France. ¹⁴⁶Necmettin Erbakan University Meram Faculty of Medicine Department of Pediatric Infectious Diseases, Konya, Turkey. ¹⁴⁷University Hospitals Leuven, Leuven, Belgium. ¹⁴⁸Hospices Civils de Lyon, Hôpital de la Croix-Rousses, Lyon, France. ¹⁴⁹Hôpital Erasme, Brussels, Belgium. ¹⁵⁰CH Gonesse, Gonesse, France. ¹⁵¹Vascular Medicine, Georges Pompidou Hospital, APHP, Paris, France. ¹⁵²Division of Pulmonary and Critical Care, University of Miami, Miami, FL, USA. ¹⁵³Guanarome Health Care Center, Canarian Health System, Las Palmas de Gran Canaria, Spain. ¹⁵⁴Regional University Hospital of Málaga, Málaga, Spain. ¹⁵⁵Aix-Marseille Université, Marseille, France. ¹⁵⁶Department of General Paediatrics, Hôpital Bicêtre, AP-HP, University of Paris Saclay, Le Kremlin-Bicêtre, France. ¹⁵⁷Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium. ¹⁵⁸CHU de La Timone, Marseille, France. ¹⁵⁹Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal. ¹⁶⁰Infectious Diseases Horizontal Technology Centre, A*STAR, Singapore Immunology Network, A*STAR, Singapore. ¹⁶¹Department of Pediatrics, Complejo Hospitalario Universitario Insular-Materno Infantil, Canarian Health System, Las Palmas de Gran Canaria, Spain. ¹⁶²Regional University Hospital of Málaga, Málaga, Spain. ¹⁶³Hospital Universitario Marqués de Valdecilla, Santander, Spain. ¹⁶⁴Faculty of Medicine, Ataturk University, Erzurum, Turkey. ¹⁶⁵Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey. ¹⁶⁶Department of Biosciences and Nutrition, Karolinska Institutet, SE14183, Stockholm, Sweden. ¹⁶⁷L'Hôpital Foch, Suresnes, France. ¹⁶⁸Department of Immunology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre imas12, Madrid, Spain. ¹⁶⁹APHF Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France. ¹⁷⁰Neurometabolic Diseases Laboratory, IDIBELL-Hospital Duran i Reynals, Barcelona; CIBERER U759, ISCIII, Madrid, Spain. ¹⁷¹Hospices Civils de Lyon, Lyon, France. ¹⁷²Université de Lille, Inserm U1285, CHU Lille, Paris, France. ¹⁷³Department of General Pediatrics, University Hospital Robert Debré, APHP, Paris, France. ¹⁷⁴Necmettin Erbakan University, Konya, Turkey. ¹⁷⁵Germans Trias i Pujol Hospital, Badalona, Spain. ¹⁷⁶Medical Intensive Care Unit, Hôpital de la Croix-Rousses, Hospices Civils de Lyon, Lyon, France. ¹⁷⁷Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. ¹⁷⁸Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain. ¹⁷⁹University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain. ¹⁸⁰Neurometabolic Diseases Laboratory, IDIBELL-Hospital Duran i Reynals, Barcelona, Spain. ¹⁸¹APHF Hôpitaux Universitaires Paris-Sud, Paris, France. ¹⁸²Virology Unit, Université de Paris, Cohin Hospital, APHP, Paris, France. ¹⁸³Hospital San Pedro, Logroño, Spain. ¹⁸⁴Respiratory Medicine, Georges Pompidou Hospital, APHP, Paris, France. ¹⁸⁵Department of Immunology, Hospital Clínico San Carlos, Madrid, Spain. ¹⁸⁶Service de Médecine Intensive Réanimation, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France. ¹⁸⁷CHRU de Nancy, Hôpital d'Enfants, Vandoeuvre, France. ¹⁸⁸Chair of Nephrology, University of Brescia, Brescia, Italy. ¹⁸⁹Department of Immunology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague,

Children's Research Institute, Victoria, Australia. ¹⁸University of São Paulo, São Paulo, Brazil. ¹⁹Washington University School of Medicine, St. Louis, MO, USA. ²⁰The American Genome Center; Uniformed Services University of the Health Sciences, Bethesda, MD, USA. ²¹Centre for Bioinformatics and System Biology, Department of Life Sciences, Imperial College London, South Kensington Campus, London, UK. ²²University of California, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA. ²³Bai Jerbai Wadia Hospital for Children, Mumbai, India. ²⁴School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. ²⁵Instituto Nacional de Pediatría (National Institute of Pediatrics), Mexico City, Mexico. ²⁶Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland. ²⁷Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Canarian Health System, Santa Cruz de Tenerife, Spain. ²⁸University of Antioquia, Medellín, Colombia. ²⁹Feinstein Institute for Medical Research, Northwell Health USA, Manhasset, NY, USA. ³⁰Department of Paediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent (CPiG), PID Research Lab, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Edegem, Belgium. ³¹The Genetics Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. ³²Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, UAE. ³³Institute for Systems Biology, Seattle, WA, USA. ³⁴Children's Hospital of Philadelphia, Philadelphia, PA, USA. ³⁵Anschutz Medical Campus, Aurora, CO, USA. ³⁶Riken, Tokyo, Japan. ³⁷Hellenic Pasteur Institute, Athens, Greece. ³⁸University of Tartu, Tartu, Estonia. ³⁹Chang Gung University, Taoyuan County, Taiwan. ⁴⁰The University of Hong Kong, Hong Kong, China. ⁴¹Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. ⁴²Yale School of Medicine, New Haven, CT, USA. ⁴³New York Genome Center, New York, NY, USA. ⁴⁴Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁴⁵Semmelweis University Budapest, Budapest, Hungary. ⁴⁶KU Leuven, Department of Immunology, Microbiology and Transplantation, Leuven, Belgium. ⁴⁷Columbia University Medical Center, New York, NY, USA. ⁴⁸University Clinic for Children's Diseases, Skopje, North Macedonia. ⁴⁹Aarhus University, Aarhus, Denmark. ⁵⁰Tokyo Medical & Dental University Hospital, Tokyo, Japan. ⁵¹Singapore Immunology Network, Singapore. ⁵²National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. ⁵³Bambino Gesù Children's

Hospital, Rome, Italy. ⁵⁴Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy. ⁵⁵Trinity College, Dublin, Ireland. ⁵⁶Hiroshima University, Hiroshima, Japan. ⁵⁷Bilkent University, Ankara, Turkey. ⁵⁸Laboratory of Immunogenetics of Human Diseases, Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz Hospital, Madrid, Spain. ⁵⁹IBB-CSIC, IDIBAPS, Barcelona, Spain. ⁶⁰Faculdades Pequeno Príncipe e Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil. ⁶¹Neurometabolic Diseases Laboratory, IDIBELL-Hospital Duran I Reynals; Catalan Institution for Research and Advanced Studies (ICREA); CIBERER U759, ISCIII Madrid Spain, Barcelona, Spain. ⁶²Institut Pasteur (CNRS UMR2000) and Collège de France, Paris, France. ⁶³Infectious Diseases Horizontal Technology Center and Singapore Immunology Network, Agency for Science Technology (A*STAR), Singapore. ⁶⁴Medical Genetics, University of Siena, Siena, Italy; Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Italy; GEN-COVID Multicenter Study. ⁶⁵Hospital Universitario de Gran Canaria Dr. Negrín, Canarian Health System, Canary Islands, Spain. ⁶⁶Imperial College London, London, UK. ⁶⁷Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. ⁶⁸Saeed Pathobiology and Genetic Lab, Tehran, Iran. ⁶⁹Uniformed Services University of the Health Sciences, Bethesda, MD, USA. ⁷⁰Hospital Universitari Vall d'Hebron, Barcelona, Spain. ⁷¹University Medical Center Utrecht, Amsterdam, The Netherlands. ⁷²Garvan Institute of Medical Research, Sydney, Australia. ⁷³The University of British Columbia, Vancouver, Canada. ⁷⁴Holy Family Red Crescent Medical College; Centre for Precision Therapeutics, NeuroGen Children's Healthcare; Genetics and Genomic Medicine Centre, NeuroGen Children's Healthcare, Dhaka, Bangladesh. ⁷⁵Mohammed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, UAE; The Centre for Applied Genomics, Department of Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada. ⁷⁶Amsterdam UMC, University of Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam, The Netherlands. ⁷⁷University of California, San Francisco, CA, USA. ⁷⁸McGill University Health Centre, Montreal, Canada. ⁷⁹Charité-Berlin University Hospital Center, Berlin, Germany. ⁸⁰Molecular Biophysics Division, Faculty of Physics, A. Mickiewicz University, Uniwersytetu Poznańskiego 2, Poznań, Poland.

⁸¹Rockefeller University, Howard Hughes Medical Institute, Necker Hospital, New York, NY, USA.

*Leaders of the COVID Human Genetic Effort.

NIAID-USUHS/TAGC COVID Immunity Group Huie Jing^{1,2}, Wesley Tung^{1,2}, Christopher R. Luthers³, Brady M. Bauman³, Samantha Shafer^{2,4}, Lixin Zheng^{2,4}, Zinan Zhang^{2,4}, Satoshi Kubo^{2,4}, Samuel D. Chauvin^{2,4}, Kazuyuki Meguro^{1,2}, Elana Shaw^{1,2}, Michael Lenardo^{2,4}, Justin Lack⁵, Eric Karlins⁶, Daniel M. Hupal⁷, John Rosenberger⁷, Gauthaman Sukumar⁷, Matthew D. Wilkerson⁷, Xijun Zhang⁷

¹Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA. ²NIAID Clinical Genomics Program, National Institutes of Health, Bethesda, MD, USA. ³Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. ⁴Laboratory of Immune System Biology, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA. ⁵NIAID Collaborative Bioinformatics Resource, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA. ⁶Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, NIAID, NIH, Bethesda, MD, USA. ⁷The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

SUPPLEMENTARY MATERIALS

science.sciencemag.org/content/370/6515/eabd4570/suppl/DC1

Materials and Methods

Figs. S1 to S11

Tables S1 and S2

References (42 and 43)

MDAR Reproducibility Checklist

[View/request a protocol for this paper from Bio-protocol.](#)

22 June 2020; accepted 16 September 2020

Published online 24 September 2020

10.1126/science.abd4570

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Qian Zhang, Paul Bastard, Zhiyong Liu, Jérémie Le Pen, Marcela Moncada-Velez, Jie Chen, Masato Ogishi, Ira K. D. Sabli, Stephanie Hodeib, Cecilia Korol, Jérémie Rosain, Kaya Bilguvar, Junqiang Ye, Alexandre Bolze, Benedetta Bigio, Rui Yang, Andrés Augusto Arias, Qinhu Zhou, Yu Zhang, Fanny Onodi, Sarantis Korniotis, Léa Karpf, Quentin Philippot, Marwa Chbihi, Lucie Bonnet-Madin, Karim Dorgham, Nikaia Smith, William M. Schneider, Brandon S. Razooky, Hans-Heinrich Hoffmann, Eleftherios Michailidis, Leen Moens, Ji Eun Han, Lazaro Lorenzo, Lucy Bizien, Philip Meade, Anna-Lena Neehus, Aileen Camille Ugurbil, Aurélien Corneau, Gaspard Kerner, Peng Zhang, Franck Rapaport, Yoann Seeleuthner, Jeremy Manry, Cecile Masson, Yohann Schmitt, Agatha Schlüter, Tom Le Voyer, Taushif Khan, Juan Li, Jacques Fellay, Lucie Roussel, Mohammad Shahrooei, Mohammed F. Alosaimi, Davood Mansouri, Haya Al-Saud, Fahd Al-Mulla, Feras Almourfi, Saleh Zaid Al-Muhsen, Fahad Alsohime, Saeed Al Turki, Rana Hasanato, Diederik van de Beek, Andrea Biondi, Laura Rachele Bettini, Mariella D'Angio', Paolo Bonfanti, Luisa Imberti, Alessandra Sottini, Simone Paghera, Eugenia Quiros-Roldan, Camillo Rossi, Giuseppe Novelli, Sami Hraiech, Yacine Tandjaoui-Lambiotte, Xavier Duval, Cédric Laouénan, COVID-STORM Clinicians, COVID Clinicians, Imagine COVID Group, French COVID Cohort Study Group, CoV-Contact Cohort, Amsterdam UMC Covid-19 Biobank, COVID Human Genetic Effort, NIAID-USUHS/TAGC COVID Immunity Group, Andrew L. Snow, Clifton L. Dalgard, Joshua D. Milner, Donald C. Vinh, Trine H. Mogensen, Nico Marr, Andrés N. Spaan, Bertrand Boisson, Stéphanie Boisson-Dupuis, Jacinta Bustamante, Anne Puel, Michael J. Ciancanelli, Isabelle Meyts, Tom Maniatis, Vassili Soumelis, Ali Amara, Michel Nussenzweig, Adolfo García-Sastre, Florian Krammer, Aurora Pujol, Darragh Duffy, Richard P. Lifton, Shen-Ying Zhang, Guy Gorochoy, Vivien Béziat, Emmanuelle Jouanguy, Vanessa Sancho-Shimizu, Charles M. Rice, Laurent Abel, Luigi D. Notarangelo, Aurélie Cobat, Helen C. Su and Jean-Laurent Casanova

Science **370** (6515), eabd4570.

DOI: 10.1126/science.abd4570originally published online September 24, 2020

The genetics underlying severe COVID-19

The immune system is complex and involves many genes, including those that encode cytokines known as interferons (IFNs). Individuals that lack specific IFNs can be more susceptible to infectious diseases. Furthermore, the autoantibody system dampens IFN response to prevent damage from pathogen-induced inflammation. Two studies now examine the likelihood that genetics affects the risk of severe coronavirus disease 2019 (COVID-19) through components of this system (see the Perspective by Beck and Aksentijevich). Q. Zhang *et al.* used a candidate gene approach and identified patients with severe COVID-19 who have mutations in genes involved in the regulation of type I and III IFN immunity. They found enrichment of these genes in patients and conclude that genetics may determine the clinical course of the infection. Bastard *et al.* identified individuals with high titers of neutralizing autoantibodies against type I IFN- α 2 and IFN- ω in about 10% of patients with severe COVID-19 pneumonia. These autoantibodies were not found either in infected people who were asymptomatic or had milder phenotype or in healthy individuals. Together, these studies identify a means by which individuals at highest risk of life-threatening COVID-19 can be identified.

Science, this issue p. eabd4570, p. eabd4585; see also p. 404

ARTICLE TOOLS

<http://science.sciencemag.org/content/370/6515/eabd4570>

SUPPLEMENTARY MATERIALS

<http://science.sciencemag.org/content/suppl/2020/09/24/science.abd4570.DC1>

Use of this article is subject to the [Terms of Service](#)

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science* is a registered trademark of AAAS.

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

**RELATED
CONTENT**

<http://stm.sciencemag.org/content/scitransmed/12/564/eabd5487.full>
<http://stm.sciencemag.org/content/scitransmed/12/554/eabc1126.full>
<http://stm.sciencemag.org/content/scitransmed/12/549/eabb9401.full>
<http://stm.sciencemag.org/content/scitransmed/12/550/eabc3539.full>
<http://science.sciencemag.org/content/sci/370/6515/404.full>
<http://science.sciencemag.org/content/sci/370/6515/eabd4585.full>

REFERENCES

This article cites 41 articles, 16 of which you can access for free
<http://science.sciencemag.org/content/370/6515/eabd4570#BIBL>

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science* is a registered trademark of AAAS.

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works